$45.955
-1.165[-2.47%]
Last update: 1:46PM Get Real Time Here
Legend Biotech
(NASDAQ:LEGN)Legend Biotech Stock (NASDAQ:LEGN), Analyst Ratings, Price Targets, Predictions
Legend Biotech Corp has a consensus price target of $58.76, established from looking at the 57 latest analyst ratings. The last 3 analyst ratings were released from Scotiabank, HC Wainwright & Co., and Cantor Fitzgerald on April 17, 2024, April 16, 2024, and April 3, 2024. With an average price target of $78 between Scotiabank, HC Wainwright & Co., and Cantor Fitzgerald, there's an implied 69.73% upside for Legend Biotech Corp from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Scotiabank
HC Wainwright & Co.
Cantor Fitzgerald
UBS
Raymond James
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Legend Biotech
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/17/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 41.44% | Scotiabank | George Farmer | $65 → $65 | Upgrade | Sector Perform → Sector Outperform | Get Alert |
| 04/16/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 89.32% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 04/03/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 78.44% | Cantor Fitzgerald | Rick Bienkowski | → $82 | Initiates | → Overweight | Get Alert |
| 04/01/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 89.32% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 03/18/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 76.26% | UBS | Ashwani Verma | $76 → $81 | Maintains | Buy | Get Alert |
| 03/18/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 89.32% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 89.32% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 03/13/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 87.14% | Raymond James | Sean McCutcheon | → $86 | Initiates | → Outperform | Get Alert |
| 03/12/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 84.96% | RBC Capital | Leonid Timashev | → $85 | Reiterates | Outperform → Outperform | Get Alert |
| 03/08/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 84.96% | RBC Capital | Leonid Timashev | → $85 | Reiterates | Outperform → Outperform | Get Alert |
| 03/07/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 84.96% | RBC Capital | Leonid Timashev | → $85 | Reiterates | Outperform → Outperform | Get Alert |
| 01/24/2024 | LEGN | Buy Now | Legend Biotech | $45.95 | 104.55% | Barclays | Gena Wang | $93 → $94 | Maintains | Overweight | Get Alert |
| 12/22/2023 | LEGN | Buy Now | Legend Biotech | $45.95 | 89.32% | HC Wainwright & Co. | Mitchell Kapoor | → $87 | Reiterates | Buy → Buy | Get Alert |
| 12/19/2023 | LEGN | Buy Now | Legend Biotech | $45.95 | 41.44% | Scotiabank | George Farmer | → $65 | Initiates | → Sector Perform | Get Alert |
| 11/15/2023 | LEGN | Buy Now | Legend Biotech | $45.95 | 89.32% | HC Wainwright & Co. | Mitchell Kapoor | $86 → $87 | Maintains | Buy | Get Alert |
| 10/18/2023 | LEGN | Buy Now | Legend Biotech | $45.95 | 102.37% | Barclays | Gena Wang | $92 → $93 | Maintains | Overweight | Get Alert |
| 10/18/2023 | LEGN | Buy Now | Legend Biotech | $45.95 | 87.14% | HC Wainwright & Co. | Mitchell Kapoor | $85 → $86 | Maintains | Buy | Get Alert |
| 08/16/2023 | LEGN | Buy Now | Legend Biotech | $45.95 | 84.96% | HC Wainwright & Co. | Mitchell Kapoor | → $85 | Reiterates | Buy → Buy | Get Alert |
| 07/21/2023 | LEGN | Buy Now | Legend Biotech | $45.95 | 84.96% | HC Wainwright & Co. | Mitchell Kapoor | $82 → $85 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Legend Biotech (LEGN)?
The latest price target for Legend Biotech (NASDAQ: LEGN) was reported by Scotiabank on April 17, 2024. The analyst firm set a price target for $65.00 expecting LEGN to rise to within 12 months (a possible 41.44% upside). 33 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Legend Biotech (LEGN)?
The latest analyst rating for Legend Biotech (NASDAQ: LEGN) was provided by Scotiabank, and Legend Biotech upgraded their sector outperform rating.
When was the last upgrade for Legend Biotech (LEGN)?
The last upgrade for Legend Biotech Corp happened on April 17, 2024 when Scotiabank raised their price target to $65. Scotiabank previously had a sector perform for Legend Biotech Corp.
When was the last downgrade for Legend Biotech (LEGN)?
The last downgrade for Legend Biotech Corp happened on January 6, 2022 when Morgan Stanley changed their price target from N/A to N/A for Legend Biotech Corp.
When is the next analyst rating going to be posted or updated for Legend Biotech (LEGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Legend Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Legend Biotech was filed on April 17, 2024 so you should expect the next rating to be made available sometime around April 17, 2025.
Is the Analyst Rating Legend Biotech (LEGN) correct?
While ratings are subjective and will change, the latest Legend Biotech (LEGN) rating was a upgraded with a price target of $65.00 to $65.00. The current price Legend Biotech (LEGN) is trading at is $45.96, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.